Navigation Links
AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R)
Date:12/11/2008

inhaled short-acting beta2-agonists. Administered twice daily, SYMBICORT is a combination of two proven asthma medications-budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA). SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.

Important Safety Information

Long acting beta2-adrenergic agonists may increase the risk of asthma-related death. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on other asthma-controller medications (e.g., low-to-medium dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies. Data from a large placebo-controlled U.S. study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting beta2-adrenergic agonist), one of the active ingredients in SYMBICORT.

SYMBICORT is not indicated for the relief of acute bronchospasm.

SYMBICORT should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma.

Particular care is needed for patients who are transferred from systemically active corticosteroids. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.

Patients who are receiving SYMBICORT twice daily should not use additional formoterol or other long-acting inhaled beta2-agonists for any reason.

Common adverse events reported in clinical trials, occurring in less than or
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015  Holographic Optical Technologies of Augusta, ... medical imaging, is entering the world of consumer electronics ... April 20 th , 2015, the campaign will introduce ... and 22-inch displays will allow consumers to view fully ... In addition to the two displays, the company will ...
(Date:3/27/2015)... , March 27, 2015 A new report from ... America – Chile , ... are top targets for IVD firms.  The healthcare research firm ... into IVD strategies for the Latin American continent with a ... globally distributed supply operations. However, the country,s regional economic clout ...
(Date:3/27/2015)... Report Details  New study shows ... What does the future hold for top companies ... new report shows you potential revenues to 2025, assessing ... 242-page report provides 185 tables, charts, and graphs. Discover ... future market prospects. Our new study lets you assess ...
Breaking Medicine Technology:Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7
(Date:3/27/2015)... Top medical tourism firm, VisitandCare.com ... the Dominican Republic to benefit from the experience of ... the medical tourism industry upside-down and becoming a choice ... services becoming the central influence. , “Trust is ... are not only attracted to low-cost surgical enhancement, but ...
(Date:3/27/2015)... 27, 2015 The report “CountryFocus ... an essential source of information on and analysis ... Germany. Germany’s increasingly elderly population and its associated ... market. In 2013, the elderly accounted for 27.1% ... Compound Annual Growth Rate (CAGR) of 1.2% to ...
(Date:3/27/2015)... March 27, 2015 DrugDev announced company ... Easy was named to the 2015 Philadelphia Business Journal ... list spotlights 40 dynamic, up-and-coming leaders less than 40 ... involvement. Winners are honored at an awards program in ... Philadelphia Business Journal. , Lyn Kremer, Publisher of the ...
(Date:3/27/2015)... According to Health Day , ... Neonatal Abstinence Syndrome (NAS) are causing alarm for Florida ... withdrawal process for a month of their lives- and ... and vomiting. The condition is precipitated by drug use ... treatment (and employing medically assisted drug treatment) will also ...
(Date:3/27/2015)... 2015 California’s ongoing worst ever drought, ... and the United States Northeast, are both manifestations of ... atmosphere is creating changes in the atmosphere’s “energy balance,” ... former NASA researcher, speaking on the Sharon Kleyne Hour™ ... only a warmer and dryer global climate but also ...
Breaking Medicine News(10 mins):Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 2Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3
... , , SALT LAKE ... it has added 10 new sales representatives to its nationwide direct sales ... , , "We,re thrilled to be adding so ... vice president of sales and marketing at Dynatronics. "This is just ...
... , , EMERYVILLE, Calif., ... ) today announced that it will webcast an investor briefing ... Time. Speakers will review clinical data for Nexavar in breast ... 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress in ...
... , , C.S. Mott Children,s Hospital ... to have their children vaccinated against H1N1 flu, despite higher disease risk; ... ANN ARBOR, Mich., Sept. 24 With schools back in session, H1N1 ... children. A new vaccine against H1N1 flu -- strongly recommended for kids ...
... , , SAN ... company discovering and developing a new class of naturally occurring ... in Tokyo on Tuesday October 6. Jeff Watkins, CEO of ... product engine, and lead program based on naturally occurring resected ...
... N.J., Sept. 24 Marketing Technology Solutions , ... QualityHealth.com , has today filed a lawsuit alleging that ... misappropriated trade secrets and other confidential information by utilizing MTS-copyrighted online ... a health website owned and operated by MediZine. , , ...
... Singapore and Washington DC (September 24, 2009) There is clear ... cancer, according to a study published in the current issue ... The article "Lifestyle Interventions in the Prevention and Treatment ... common forms of cancer (lung, colorectal, breast, prostate and skin) ...
Cached Medicine News:Health News:Dynatronics Expands Nationwide Direct Sales Force by 25 Percent 2Health News:H1N1 Flu: Are Parents Underestimating Risk to Kids? 2Health News:H1N1 Flu: Are Parents Underestimating Risk to Kids? 3Health News:H1N1 Flu: Are Parents Underestimating Risk to Kids? 4Health News:aTyr Pharma to Present at Japan Biopharma Partnering Conference 2Health News:MediZine Named in Intellectual Property Lawsuit Filed by Marketing Technology Solutions 2
For the quantitative determination of alkaline phosphatase in human serum....
Auto LDL-Cholesterol, automated analyzer test kits....
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
Medicine Products: